PRTCY (PRTCY) Stock Price & Analysis
PRTCY (PRTCY) rose 0.18% to USD 16.43 as of June 10, 2026 at 04:07 UTC, according to Nexqual real-time market data.
PRTCY last closed at USD 16.4; the session ranged USD 16.43–16.43 on volume of 2 shares. Market capitalization is $399.94M, with a 52-week range of USD 14.5–19.92 (PNK). Source: Nexqual, June 10, 2026 at 04:07 UTC.
Key Statistics (as of June 10, 2026 at 04:07 UTC)
| Price | USD 16.43 |
|---|---|
| Change | ▲ 0.18% (up) |
| Previous Close | USD 16.4 |
| Open | USD 16.43 |
| Day Range | USD 16.43 – 16.43 |
| 52-Week Range | USD 14.5 – 19.92 |
| Volume | 2 shares |
| Market Cap | $399.94M |
| Exchange | PNK |
Technical Analysis (PRTCY)
Nexqual's technical model rates PRTCY "SELL" based on 1 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 04:07 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 42.66 (neutral) |
| vs SMA50 | Below (USD 17.16) |
| MACD | -0.05 (negative) |
Analyst Ratings (PRTCY)
Wall Street analysts rate PRTCY "None", per Nexqual as of June 10, 2026 at 04:07 UTC.
| Consensus Rating | None |
|---|
Earnings (PRTCY)
Source: Nexqual, June 10, 2026 at 04:07 UTC.
Financials & Fundamentals (PRTCY)
| Total Revenue | $4.66M |
|---|---|
| Revenue Growth (YoY) | -38.20% |
| Gross Margin | +0.00% |
| Operating Margin | -1797.79% |
| Profit Margin | +0.00% |
| ROE | -30.85% |
| Debt / Equity | 66.49 |
| Current Ratio | 6.59 |
| Total Cash | $288.72M |
| Total Debt | $203.26M |
| Free Cash Flow | $-89.99M |
Source: Nexqual, June 10, 2026 at 04:07 UTC.
Financial Health Score (PRTCY)
Nexqual rates PRTCY's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 04:07 UTC.
| Growth | Weak — Revenue -4% YoY (annual), declining |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $289M cash vs $203M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$90M, burning cash |
| Efficiency | Critical — ROE -31%, ROA -10.8% |
Ownership (PRTCY)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.58% |
| Shares Outstanding | 24.34M |
| Float | 15.74M |
| Short % of Float | +0.12% |
Source: Nexqual, June 10, 2026 at 04:07 UTC.
Leadership (PRTCY)
PRTCY is led by Robert Lyne J.D., L.L.B. (age 42), CEO & Director, per Nexqual as of June 10, 2026 at 04:07 UTC.
| CEO & Director | Robert Lyne J.D., L.L.B. (age 42) |
|---|---|
| Co-Founder & Non-Executive Director | Robert S. Langer Jr., Ph.D., ScD (age 76) |
| Co-Founder & President | Eric Elenko (age 52) |
| Chief Financial Officer | Lauren A. White (age 46) |
| COO, General Counsel & Company Secretary | Charles Sherwood III |
Major Backers & Investors (PRTCY)
Notable institutional backers of PRTCY include Pentwater Capital Management Lp, Millennium Management, according to Nexqual as of June 10, 2026 at 04:07 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Pentwater Capital Management Lp | 0.29% |
| Millennium Management | 0.24% |
Source: Nexqual, June 10, 2026 at 04:07 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SLN | Silence Therapeutics Plc - Amer | USD 6.01 | ▼ 2.59% |
| KROS | Keros Therapeutics, Inc. | USD 10.07 | ▼ 2.23% |
| MOLN | Molecular Partners AG | USD 3.88 | ▼ 5.37% |
| PHVS | Pharvaris N.V. | USD 31.6 | ▲ 1.64% |
| PHAR | Pharming Group N.V. | USD 12.59 | ▲ 0.39% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 04:07 UTC. This page is informational and not investment advice.